UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 7 von 43
Datensatz exportieren als...
BibTeX
Biliary cancer: Utility of next‐generation sequencing for clinical management
Cancer, 2016-12, Vol.122 (24), p.3838-3847
Javle, Milind
Bekaii‐Saab, Tanios
Jain, Apurva
Wang, Ying
Kelley, Robin Katie
Wang, Kai
Kang, Hyunseon C.
Catenacci, Daniel
Ali, Siraj
Krishnan, Sunil
Ahn, Daniel
Bocobo, Andrea Grace
Zuo, Mingxin
Kaseb, Ahmed
Miller, Vincent
Stephens, Philip J.
Meric‐Bernstam, Funda
Shroff, Rachna
Ross, Jeffrey
2016
Details
Autor(en) / Beteiligte
Javle, Milind
Bekaii‐Saab, Tanios
Jain, Apurva
Wang, Ying
Kelley, Robin Katie
Wang, Kai
Kang, Hyunseon C.
Catenacci, Daniel
Ali, Siraj
Krishnan, Sunil
Ahn, Daniel
Bocobo, Andrea Grace
Zuo, Mingxin
Kaseb, Ahmed
Miller, Vincent
Stephens, Philip J.
Meric‐Bernstam, Funda
Shroff, Rachna
Ross, Jeffrey
Titel
Biliary cancer: Utility of next‐generation sequencing for clinical management
Ist Teil von
Cancer, 2016-12, Vol.122 (24), p.3838-3847
Ort / Verlag
United States
Erscheinungsjahr
2016
Link zum Volltext
Quelle
Free E-Journal (出版社公開部分のみ)
Beschreibungen/Notizen
BACKGROUND Biliary tract cancers (BTCs) typically present at an advanced stage, and systemic chemotherapy is often of limited benefit. METHODS Hybrid capture–based comprehensive genomic profiling (CGP) was performed for 412 intrahepatic cholangiocarcinomas (IHCCAs), 57 extrahepatic cholangiocarcinomas (EHCCAs), and 85 gallbladder carcinomas (GBCAs). The mutational profile was correlated with the clinical outcome of standard and experimental therapies for 321 patients. Clinical variables, detected mutations, and administered therapies were correlated with overall survival (OS) in a Cox regression model. RESULTS The most frequent genetic aberrations (GAs) observed were tumor protein 53 (TP53; 27%), cyclin‐dependent kinase inhibitor 2A/B (CDKN2A/B; 27%), KRAS (22%), AT‐rich interactive domain‐containing protein 1A (ARID1A; 18%), and isocitrate dehydrogenase 1 (IDH1; 16%) in IHCCA; KRAS (42%), TP53 (40%), CDKN2A/B (17%), and SMAD4 (21%) in EHCCA; and TP53 (59%), CDKN2A/B (19%), ARID1A (13%), and ERBB2 (16%) in GBCA. Fibroblast growth factor receptor (FGFR; 11%) and IDH mutations (20%) were mostly limited to IHCCA but appeared to be mutually exclusive. In the IHCCA group, TP53 and KRAS mutations were associated significantly with poor OS, whereas FGFR2 mutations were associated with improved OS (P = .001), a younger age at onset, and female sex. IDH1/2 mutations were not prognostic. In a multivariate model, the effects of TP53 and FGFR GAs remained significant (P < .05). Patients with FGFR GAs had superior OS with FGFR‐targeted therapy versus standard regimens (P = .006). Targeted therapy in IHCCA was associated with a numerical OS improvement (P = .07). CONCLUSIONS This is the largest clinically annotated data set of BTC cases with CGP and indicates the potential of CGP for improving outcomes. CGP should be strongly considered in the management of BTC patients. Cancer 2016;122:3838–3847. © 2016 American Cancer Society. This is the largest clinically annotated data set of biliary tract cancer cases with comprehensive genomic profiling, and it indicates the potential of comprehensive genomic profiling to improve outcomes. Comprehensive genomic profiling should be strongly considered in the management of patients with biliary tract cancer.
Sprache
Englisch
Identifikatoren
ISSN: 0008-543X
eISSN: 1097-0142
DOI: 10.1002/cncr.30254
Titel-ID: cdi_proquest_miscellaneous_1855077026
Format
–
Schlagworte
AT‐rich interactive domain‐containing protein 1A (ARID1A)
,
Bile Duct Neoplasms - genetics
,
Bile Duct Neoplasms - therapy
,
biliary tract cancers
,
Cholangiocarcinoma - genetics
,
comprehensive genomic profiling
,
Cyclin-Dependent Kinases - genetics
,
Female
,
fibroblast growth factor receptor 2 (FGFR2)
,
Gallbladder Neoplasms - genetics
,
High-Throughput Nucleotide Sequencing - methods
,
Humans
,
isocitrate dehydrogenase 1/2 (IDH1/2)
,
Male
,
Middle Aged
,
Molecular Targeted Therapy - methods
,
Mutation - genetics
,
Neoplasm Proteins - genetics
,
prognosis
,
Signal Transduction - genetics
,
targeted therapy
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX